Last edition
News about "Biotron announces its lead clinical asset, BIT225 "
Biotron Limited, a company engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need, announced that the company?s lead clinical asset, BIT225, has demonstrated substantial and clinically meaningful efficacy against SARS-CoV-2 in a series of animal and cell-based studies performed
Biotron Announces Its Lead Clinical Asset, BIT225 | 29/11/2021 | By Darshana | 191
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members